gilteritinib
Selected indexed studies
- Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. (J Clin Oncol, 2024) [PMID:38277619]
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. (N Engl J Med, 2019) [PMID:31665578]
- Gilteritinib. (, 2012) [PMID:31643742]
_Worker-drafted node — pending editorial review._
Connections
No connections recorded yet.
Sources
- Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML. (2024) pubmed
- Gilteritinib or Chemotherapy for Relapsed or Refractory FLT3-Mutated AML. (2019) pubmed
- Gilteritinib. (2012) pubmed
- Gilteritinib as Post-Transplant Maintenance for AML With Internal Tandem Duplication Mutation of FLT3. (2024) pubmed
- Gilteritinib. (2006) pubmed
- Gilteritinib: First Global Approval. (2019) pubmed
- Measurable residual disease and posttransplantation gilteritinib maintenance for patients with FLT3-ITD-mutated AML. (2025) pubmed
- Venetoclax Plus Gilteritinib for FLT3-Mutated Relapsed/Refractory Acute Myeloid Leukemia. (2022) pubmed
- Follow-up of patients with R/R FLT3-mutation-positive AML treated with gilteritinib in the phase 3 ADMIRAL trial. (2022) pubmed
- Venetoclax synergizes with gilteritinib in FLT3 wild-type high-risk acute myeloid leukemia by suppressing MCL-1. (2022) pubmed